| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRNA | Ordinary Shares | Award | $0 | +200,000 | +8% | $0.000000 | 2,715,320 | 07 Aug 2024 | Direct | F1, F2 |
| transaction | VRNA | Ordinary Shares | Tax liability | $230,308 | -87,904 | -3.2% | $2.62 | 2,627,416 | 07 Aug 2024 | Direct | F1, F3, F4, F5 |
| Id | Content |
|---|---|
| F1 | Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| F2 | Represents an award of Ordinary Shares upon vesting of Performance Restricted Share Units in connection with the Issuer's first commercial sale of ensifentrine. |
| F3 | Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of the Performance Restricted Share Units described in footnote 2 above. |
| F4 | The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on August 6, 2024 divided by eight (8). |
| F5 | Consists of (i) 635,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 79,375 ADSs); and (ii) 1,992,416 Ordinary Shares underlying 249,052 ADSs. |